BASEL, Switzerland, Aug. 13, 2020 — Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF) is expanding its presence in Europe. The leading neuro-pharmaceutical company for psychedelic inspired medicines will open an operating subsidiary in Switzerland that will oversee clinical development, scientific collaborations and the expansion of MindMed’s business in Europe. As part of the ramp up and planning process for its growing global pipeline of clinical programs of psychedelic inspired medicines, MindMed’s board of directors has appointed Dr. Miri Halperin Wernli as President to help guide MindMed’s clinical development strategy and provide further leadership to its R&D pipeline.
Dr. Halperin Wernli will be tasked with expanding the clinical and scientific team in Europe. Her immediate primary leadership responsibilities center around the company’s LSD microdosing program and Project Lucy, the LSD experiential therapy program for anxiety disorders. Dr. Halperin Wernli will also help implement R&D collaborations in Europe which include the company’s partnership with the University Hospital Basel’s Liechti Lab.
Dr. Miri Halperin Wernli said: “I am very excited to help scale MindMed’s R&D as we seek to prove to governments and society that psychedelic inspired medicines and therapies can play a vital role in addressing the growing global mental health and addiction crisis. I passionately believe psychedelic inspired medicines and therapies have immense potential to redefine society’s approach to mental health. Many mental health disorders appear to be interconnected which presents a unique opportunity to MindMed to innovate and create novel treatment paradigms for various severe and chronic mental health conditions which have poor and unsatisfactory therapeutic offerings at present.”
Dr. Halperin Wernli is a senior pharmaceutical and biomedical executive with over 30 years of strategic and operational leadership in the biopharmaceutical industry and a deep understanding of drug and product development in heavy regulated environments. Dr. Halperin Wernli has held worldwide senior leadership positions in product development, R&D and Strategic Marketing throughout Switzerland and in the United States at leading pharmaceutical companies including Merck, Sharp & Dohme, Roche, and Actelion Pharmaceuticals. In addition to her roles in drug development in the pharma industry, Dr. Halperin Wernli has a depth of clinical experience in child and adult psychiatry in hospital settings in Switzerland and Canada.
Dr. Halperin Wernli previously co-founded and led Creso Pharma, an Australian listed medical cannabis company with operations in Europe and Canada.
MindMed Co-Founder and Co-CEO JR Rahn said: “It is a real honor for our company to be able to welcome Dr. Halperin Wernli. She brings a wealth of experience, knowledge and leadership in our approach for patients and her expertise will help us to continue to pioneer the fast-growing psychedelic inspired medicine market.”
Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic-inspired medicines to improve health, promote wellness and alleviate suffering. The company has initiated or is initiating studies to evaluate potential treatments to help patients with ADHD, anxiety, cluster headaches and substance abuse. The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines. MindMed trades on the NEO Exchange under the symbol MMED. MindMed can also be traded in the US under the symbol OTC: MMEDF and in Germany under the symbol DE:MMQ. For more information: www.mindmed.co.
MindMed Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and performance of Mind Medicine (MindMed) Inc. (“MindMed”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, MindMed’s and its collaborators’ ability to continue to conduct research and clinical programs, MindMed’s ability to manage its supply chain, product sales of products marketed by MindMed and/or its collaborators (collectively, ” Products”), and the global economy; the nature, timing, and possible success and therapeutic applications of Products and Product candidates and research and clinical programs now underway or planned; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Product candidates and new indications for Products; unforeseen safety issues resulting from the administration of Products and Product candidates in patients, including serious complications or side effects in connection with the use of MindMed’s Products and product candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict MindMed’s ability to continue to develop or commercialize Products; ongoing regulatory obligations and oversight impacting Products, research and clinical programs, and business, including those relating to patient privacy; uncertainty of market acceptance and commercial success of Products and Product candidates and the impact of studies on the commercial success of Products and Product candidates; the availability and extent of reimbursement of Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; competing drugs and product candidates that may be superior to Products and Product candidates; the extent to which the results from the research and development programs conducted by MindMed or its collaborators may be replicated in other studies and lead to therapeutic applications; the ability of MindMed to manufacture and manage supply chains for multiple products and product candidates; the ability of MindMed’s collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labelling, distribution, and other steps related to MindMed’s Products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of MindMed to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, other litigation and other proceedings and government investigations relating to MindMed and its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on MindMed’s business, prospects, operating results, and financial condition. Any forward-looking statements are made based on management’s current beliefs and judgment. MindMed does not undertake any obligation to update publicly any forward-looking statement.
Media Contact: Anna Walsh
E: mindm[email protected]
Investor Relations: [email protected]
View original content to download multimedia:http://www.prnewswire.com/news-releases/mindmed-expanding-rd-in-europe-appoints-dr-miri-halperin-wernli-as-president-301111575.html
SOURCE Mind Medicine (MindMed) Inc.